• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Schizophrenia incidence sharply increased following cannabis legalization

bySiwen LiuandAlex Chan
February 14, 2025
in Chronic Disease, Neurology, Pediatrics Classics, Psychiatry, Public Health, QX Custom, Restricted
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. After cannabis policy legalization, incident cases of schizophrenia linked to cannabis use disorder nearly tripled.

Evidence Rating Level: 2 (Good)

The use of cannabis has been associated with the development of psychosis and schizophrenia. However, the association between cannabis legalization and psychosis is unclear. This retrospective cohort study thus examined how population-attributable risk fraction (PARF) for cannabis use disorder (CUD) associated with schizophrenia changed over time after medical cannabis liberalization and nonmedical cannabis legalization in Canada. Using routinely collected health administrative data of residents aged 14-65 from the province of Ontario, Canada, this study examined annual changes in the PARF of schizophrenia associated with CUD between January 1, 2006, and December 31, 2022. Three policy periods were analyzed: prelegalization (Jan 2006–Nov 2015), cannabis liberalization (Dec 2015–Sep 2018), and nonmedical legalization (Oct 2018–Dec 2022). The primary outcome was diagnosis of schizophrenia and the secondary outcome was diagnosis of psychosis not otherwise specified (NOS). This study included a total of 13,588,681 individuals (mean [SD] age, 39.3 [16.1] years; 6,804,906 males [50.1%]), of whom 118,650 (0.9%) had CUD. In total, 91,106 individuals (0.7%) developed schizophrenia (10,583 of 118,650 [8.9%] with CUD vs 80,523 of 13,470,031 [0.6%] without CUD). The PARF of CUD associated with schizophrenia nearly tripled from 3.7% (95% CI, 2.7%-4.7%) prelegalization to 10.3% (95% CI, 8.9%-11.7%) postlegalization. The overall incidence of schizophrenia per 100,000 individuals remained stable between the prelegalization (53.5) and postlegalization (53.3) periods, while the incidence of psychosis NOS increased by 60.2%, from 33.9 to 54.3. The largest absolute increase in PARF occurred among individuals aged 19 to 24 years, which increased in males from 8.5% (95% CI, 6.7%-10.3%) to 18.9% (95% CI, 16.8%-21.0%) and in females from 4.8% (95% CI, 3.3%-6.3%) to 12.0% (95% CI, 9.5%-14.6%). Overall, this study found that during a period of cannabis policy liberalization, incident cases of schizophrenia linked to CUD nearly tripled. Future research is needed to examine the long-term impact of cannabis policy changes on the incidence of psychotic disorders. 

Click to read the study in JAMA Network Open

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Upper extremity pain associated with poor functional recovery post-stroke

Exenatide does not slow Parkinson’s disease progression compared to placebo

2 Minute Medicine Rewind April 21, 2025

Tags: cannabisneurologypsychiatrypublic healthschizophrenia
Previous Post

#VisualAbstract: Apixaban is Superior to Aspirin for Stroke Prevention in People with Subclinical Atrial Fibrillation

Next Post

2 Minute Medicine Rewind February 17, 2025

RelatedReports

Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Chronic Disease

Upper extremity pain associated with poor functional recovery post-stroke

April 25, 2025
Levodopa for Parkinson’s disease more effective than newer generation therapies
Chronic Disease

Exenatide does not slow Parkinson’s disease progression compared to placebo

April 25, 2025
Weekly Rewinds

2 Minute Medicine Rewind April 21, 2025

April 25, 2025
Food environment associated with gestational diabetes
Chronic Disease

Spot capillary HbA1c testing may have a role in early detection of type 2 diabetes

April 10, 2025
Next Post
Poverty, preterm birth demonstrate additive effect on cognition

2 Minute Medicine Rewind February 17, 2025

Radiographic surrogates may predict tumor-specific survival in renal carcinoma

Bristol Myers Squibb: Opdivo-Qvantig is the first FDA approved subcutaneous version of cancer immunotherapy targeting PD-1

No obesity paradox found between BMI, stroke, and death

Artificial intelligence-powered documentation fails to significantly improve clinician efficiency

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Upper extremity pain associated with poor functional recovery post-stroke
  • Exenatide does not slow Parkinson’s disease progression compared to placebo
  • #VisualAbstract: Inebilizumab Improves Outcomes in Generalized Myasthenia Gravis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.